Bookmark

Add to MyYahoo RSS

Advanced Transit Dynamics News

News on Advanced Transit Dynamics (Ticker: JNJ) continually updated from thousands of sources around the net.

Thursday Jul 17 | BioSpace

Johnson & Johnson Spinout Zosano Pharma, Inc. Sets Terms For $70 Million IPO

Zosano Pharma, a biotech developing a transdermal delivery system to treat osteoporosis, announced terms for its IPO on Wednesday.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Startups, LOC-AID Technologies, Conor Medsystems

Wed Jul 16, 2014

Daily Kos

Three Documentary Films All Progressives Should See, Learn & Memorize

As part of another diary I brought up several excellent sources of Truth, Reality and Knowledge and today I re-post that information purely for it's own sake because I truly believe - it's worth the effort and benefit that it may impart to all those who are willing to listen and capable of comprehending the message.

Comment?

Related Topix: Action Movies, Comedy Movies, Thriller, The One, Science Fiction Movies, Aria Systems, LOC-AID Technologies, George Bush, Netflix, Startups

Wall St. Cheat Sheet

Does Johnson & Johnson Belong in Your Portfolio?

The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Tue Jul 15, 2014

Reuters

UPDATE 3-J&J beats forecasts, helped by new hepatitis C drug

Johnson & Johnson reported higher-than-expected quarterly results on sizzling sales of its new Olysio treatment for hepatitis C, but company officials cautioned the pill will lose steam later this year as newer rivals come to market.

Comment?

Related Topix: Food, J and J Snack Foods, Hepatitis, Medicine, Health, Johnson & Johnson, Biotech, Johnson and Johnson, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry

Customer Interaction Solutions

Medivir: Continued strong market uptake for OLYSIO during the second quarter 2014

Medivir AB announces that the global second quarter net sales of Olysio amounted to 831 MUSD, of which 725 MUSD were sales in the USA.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Aria Systems, LOC-AID Technologies

TheStreet.com

Johnson & Johnson (JNJ) Falls Despite Earnings Beat, Strong Olysio Sales

Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

The Modesto Bee

Stock futures edge up following mixed retail data

Stock futures edged higher Tuesday as investors digested mixed U.S. retail sales data and several corporate earnings reports.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Carlsbad Current-Argus

J&J 2Q profit climbs 13 percent on new-drug sales

This Oct. 16 2012, file photo, shows Johnson and Johnson products, including Band Aid brand adhesive bandages, arranged for a photo in St. Petersburg, Fla.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups

Tri-cityherald.com

J&J 2Q profit climbs 13 percent

The New Brunswick, New Jersey-based company said earnings increased to $4.33 billion, or $1.51 per share, from $3.83 billion, or $1.33 per share, in the same quarter a year ago.

Comment?

Related Topix: Food, J and J Snack Foods, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups

Sun Jul 13, 2014

Seeking Alpha

Can Johnson & Johnson Cure What Ails Your Portfolio?

Johnson & Johnson is well known around the dividend growth investing community with over 50 consecutive years of dividend increases.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Seeking Alpha

Is Abbott Laboratories Better Than Johnson & Johnson For Your Dividend Portfolio?

Johnson & Johnson has the lowest volatility of any business with 25+ years of dividend payments without a reduction.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Thu Jul 10, 2014

The Motley Fool

Is This Huge Market Slowing Down?

Waiting for a recovery in the orthopedic market isn't exactly waiting for Godot, but it has been frustrating all the same.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Seeking Alpha

Earnings Preview: Johnson & Johnson Q2 2014

Johnson & Johnson is slated to report 2Q 2014 earnings before the opening bell on Tuesday, July 15th.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, OrthoClinical Diagnostics, Medical Equipment, VisionCare Ophthalmic Technologies, Startups

The Washington Post

Spinversions Make Giants Candidates to Escape U.S. Tax: Real M&A

American conglomerates that want a piece of the tax-inversion deal bonanza may start turning to a new tactic.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, LOC-AID Technologies

Philadelphia Gay News

N.J.-based corp. marks third year of LGBT initiative

Five years ago, Johnson & Johnson started hosting Gay 101 "lunch and learns" to find out more about the LGBT community as a consumer group.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

Wed Jul 09, 2014

Seeking Alpha

Has Johnson & Johnson Finally Met Its Match?

In the latest instalment of our Head-To-Head series, we pitch two companies from the health care sector, Johnson & Johnson and Covidien, against one another.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups, Johnson Controls

GigaOM

White House pulls plug on controversial Patent Office nominee after tech sector backlash

The Obama Administration has backed away from an unpopular plan to name a Johnson & Johnson executive and patent reform opponent as head of the US Patent Office.

Comment?

Related Topix: Patent / Trademark Law, Law, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups

Tue Jul 08, 2014

Montreal Gazette

Energizer Holdings to shut Montreal factory; 430 jobs gone

Just nine months after buying the east-end Johnson & Johnson factory, Energizer Holdings announced Tuesday it will shut down the facility beginning next summer.

Comment?

Related Topix: Energizer HLDGS, Electronics, Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, VisionCare Ophthalmic Technologies, Startups

BioSpace

Oxford BioTherapeutics Appoints As Head Of Clinical Development

Oxford BioTherapeutics, an international biotechnology company focused on the development of innovative antibody-drug conjugates for the treatment of cancer, announced today the appointment of Eugen Leo, MD, PhD, MBA, as Head of Clinical Development.

Comment?

Related Topix: Medicine, Cancer, Health, LOC-AID Technologies, Oncology, Colorado State University, Real Estate, ADC

BioSpace

Why This Johnson & Johnson Exec Shouldn't Be the Next U.S. Patent Office Director

Philip Johnson is Chief Intellectual Property Counsel of Johnson & Johnson, one of the largest pharmaceutical companies in the world.

Comment?

Related Topix: Johnson & Johnson, Biotech, Johnson and Johnson, Medicine, Johnson and Johnson Merck Consumer Pharmaceuticals, Healthcare Industry, Patent / Trademark Law, Law, VisionCare Ophthalmic Technologies, Startups

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••